Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopure continues Phase III trial for Hemopure:

This article was originally published in Clinica

Executive Summary

Biopure is continuing a Phase III clinical trial of its investigational oxygen therapeutic Hemopure, following an independent panel review of safety data from the halfway point of the trial. The single-blind, 640-patient study is evaluating Hemopure, which consists of ultrapurified bovine haemoglobin, as a room temperature-stable, universally compatible alternative to red blood cell transfusion in orthopaedic surgery at more than 40 sites in the US, Canada, Europe and South Africa. The Cambridge, Massachusetts-based company expects to submit the product to the US FDA for market go-ahead this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel